MNKD Share Price

Open 1.54 Change Price %
High 1.75 1 Day -0.02 -1.31
Low 1.50 1 Week -0.03 -1.95
Close 1.51 1 Month -0.01 -0.66
Volume 10721647 1 Year 0.26 20.80
52 Week High 2.38
52 Week Low 0.41
MNKD Important Levels
Resistance 2 1.74
Resistance 1 1.65
Pivot 1.59
Support 1 1.37
Support 2 1.28
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

MannKind Corporation (NASDAQ: MNKD)

MNKD Technical Analysis 4
As on 23rd Jun 2017 MNKD Share Price closed @ 1.51 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.93 & Strong Buy for SHORT-TERM with Stoploss of 1.26 we also expect STOCK to react on Following IMPORTANT LEVELS.
MNKD Target for June
1st Target up-side 2.18
2nd Target up-side 2.64
3rd Target up-side 3.1
1st Target down-side 0.86
2nd Target down-side 0.4
3rd Target down-side -0.06
MNKD Other Details
Segment EQ
Market Capital 405527936.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.mannkindcorp.com
MNKD Address
MNKD
28903 North Avenue Paine
Valencia, CA 91355
United States
Phone: 661-775-5300
MNKD Latest News
Interactive Technical Analysis Chart MannKind Corporation ( MNKD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on MannKind Corporation
MNKD Business Profile
MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. The Company�s product candidate, AFREZZA (insulin human) inhalation powder, is insulin that is in late-stage clinical investigation for the treatment of adults with type I or type II diabetes for the control of hyperglycemia. The AFREZZA inhalation powder is centered on a class of potential of hydrogen (pH)-sensitive organic molecules. AFREZZA utilizes its Technosphere formulation technology. As of December 31, 2011, MannKind had not generated any product revenues. As of December 31, 2011, the AFREZZA clinical program had involved 61 different studies of AFREZZA and over 5,600 adult patients.